Cancer Family
Precursor Lymphoid Neoplasm
CI-CAN-00000327Explore in graph →
Hematologic567 active trials12 approved drugs212 evidence items
- NCIt
- C7055
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000327Explore in graph →
Clinical trials
2,154 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (286)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05613348 | CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma(CAR19T2) | withdrawn | Phase 1 / Phase 2 | 0 | Zhujiang HospitalOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT03267030 | Asparaginase Encapsulated in Erythrocytes for Patients With ALL and Hypersensitivity to PEG-asparaginase | completed | Phase 2 | 55 | Birgitte Klug AlbertsenOTHER | 6 | Mar 15, 2024 | clinicaltrials |
| NCT01858740 | Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children | completed | Phase 2 | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT03982992 | Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab(DLI-TARGET) | withdrawn | Phase 2 | 0 | Ludwig-Maximilians - University of MunichOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT04845035 | Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | withdrawn | Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 22, 2024 | clinicaltrials |
| NCT02435849 | Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients(ELIANA) | completed | Phase 2 | 80 | Novartis PharmaceuticalsINDUSTRY | 11 | Feb 13, 2024 | clinicaltrials |
| NCT04731974 | Acute Concussion and Melatonin | unknown | Phase 2 | 254 | Children's National Research InstituteOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06220487 | A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL(ABC) | recruiting | Phase 2 | 67 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | terminated | Phase 1 / Phase 2 | 79 | Cellestia Biotech AGINDUSTRY | 6 | Jan 16, 2024 | clinicaltrials |
| NCT04785547 | ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT | terminated | Phase 2 | 3 | Prof. Christina PetersOTHER | 10 | Jan 16, 2024 | clinicaltrials |
| NCT01991457 | Fludarabine / Total Body Irradiation Regimen for ALLO HCT in Acute Lymphoblastic Leukemia(FluTBI) | completed | Phase 2 | 19 | University of Alabama at BirminghamOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT05045443 | Safety and Efficacy of Curcumin in Children With Acute Lymphoblastic Leukemia(CurcumPedALL) | completed | Phase 2 | 30 | Ain Shams UniversityOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT04956666 | A Roll-over Study to Provide Continued Treatment With Lyophilized Pegaspargase (S95014) in Pediatric Patients With Acute Lymphoblastic Leukemia (ALL)(ALL) | completed | Phase 2 | 75 | Institut de Recherches Internationales ServierOTHER | 1 | Dec 29, 2023 | clinicaltrials |
| NCT05201183 | A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Naoyuki G. Saito, M.D., Ph.D.OTHER | 1 | Dec 11, 2023 | clinicaltrials |
| NCT06141304 | Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT | unknown | Phase 2 | 28 | The First Hospital of Jilin UniversityOTHER | 1 | Nov 21, 2023 | clinicaltrials |
| NCT04145531 | An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) | completed | Phase 2 / Phase 3 | 229 | Jazz PharmaceuticalsINDUSTRY | 2 | Nov 18, 2023 | clinicaltrials |
| NCT02639559 | Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies | completed | Phase 2 | 50 | Washington University School of MedicineOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT06087419 | A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients | unknown | Phase 1 / Phase 2 | 42 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Nov 2, 2023 | clinicaltrials |
| NCT02763384 | BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma | terminated | Phase 2 | 12 | Washington University School of MedicineOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT00571662 | Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant | completed | Phase 2 | 76 | University of NebraskaOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT06081478 | CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia | recruiting | Phase 2 | 100 | Beijing Tongren HospitalOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT03096782 | Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma | completed | Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT02065869 | Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant | terminated | Phase 1 / Phase 2 | 187 | Bellicum PharmaceuticalsINDUSTRY | 2 | Sep 29, 2023 | clinicaltrials |
| NCT03733249 | Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study | terminated | Phase 1 / Phase 2 | 187 | Bellicum PharmaceuticalsINDUSTRY | 1 | Sep 26, 2023 | clinicaltrials |
| NCT00003838 | Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow | completed | Phase 2 | 202 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Sep 21, 2023 | clinicaltrials |
| NCT02661035 | Allo HSCT Using RIC for Hematological Diseases | completed | Phase 2 | 156 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT01696461 | A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor | completed | Phase 2 | 127 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Sep 14, 2023 | clinicaltrials |
| NCT01044745 | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer | terminated | Phase 2 | 20 | University of NebraskaOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT05320380 | A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat | withdrawn | Phase 1 / Phase 2 | 0 | Children's Oncology GroupNETWORK | 0 | Sep 1, 2023 | clinicaltrials |
| NCT04224571 | CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children | completed | Phase 2 | 208 | Chinese University of Hong KongOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT04029038 | Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT01616238 | A Study for Older Adults With Acute Lymphoblastic Leukaemia(UKALL60+) | completed | Phase 2 | 126 | University College, LondonOTHER | 2 | Aug 16, 2023 | clinicaltrials |
| NCT03267186 | Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant | completed | Phase 2 | 8 | Andrew RezvaniOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT02311998 | Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML | completed | Phase 1 / Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT04954326 | A Study Comparing the Blood Levels of Both Pegaspargase (S95014) Formulations (Liquid vs Lyophilized) in the Treatment of Paediatric Patients With Acute Lymphoblastic Leukemia (ALL)(ALL) | completed | Phase 2 | 89 | Institut de Recherches Internationales ServierOTHER | 1 | Jul 12, 2023 | clinicaltrials |
| NCT05931757 | A Study of Olverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALL | not yet recruiting | Phase 2 | 22 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT01572662 | Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning | completed | Phase 2 | 201 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT04562792 | Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia | completed | Phase 2 | 1 | Children's Mercy Hospital Kansas CityOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT05576532 | Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia | unknown | Phase 2 | 30 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT02935543 | CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL | terminated | Phase 2 | 1 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02396043 | Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma | unknown | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT00287105 | Safety and Efficacy of Imatinib Added to Chemotherapy in Treatment of Ph+ Acute Lymphoblastic Leukemia in Children(ESPHALL) | completed | Phase 2 | 49 | Rennes University HospitalOTHER | 1 | May 24, 2023 | clinicaltrials |
| NCT03705507 | International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia(SeluDex) | terminated | Phase 1 / Phase 2 | 12 | University of BirminghamOTHER | 3 | May 11, 2023 | clinicaltrials |
| NCT03389035 | Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT(CARCIK) | completed | Phase 1 / Phase 2 | 21 | Fondazione Matilde Tettamanti Menotti De Marchi OnlusOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT05252403 | Residual Disease Driven Strategy for CARCIK (CD19) in Adults/Pediatric BCP-ALL | unknown | Phase 2 | 35 | Fondazione Matilde Tettamanti Menotti De Marchi OnlusOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT02581007 | Reduced Intensity Conditioning Transplant Using Haploidentical Donors | completed | Phase 2 | 25 | Northside Hospital, Inc.OTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT04067518 | A Clinical Study of SHP674 (Pegaspargase) in Participants With Newly Diagnosed, Untreated Acute Lymphoblastic Leukemia | completed | Phase 2 | 28 | Institut de Recherches Internationales ServierOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT05809167 | Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCT | unknown | Phase 2 | 55 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT01256398 | Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | completed | Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Apr 4, 2023 | clinicaltrials |
| NCT01593488 | Liposomal Cytarabine in the Treatment of Central Nervous System Resistant or Relapsed Acute Lymphoblastic Leukemia in Children(CILI) | unknown | Phase 2 | 31 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Mar 18, 2024source: clinicaltrials